FDA Awards Priority Voucher for Copper Drug Treating Kids' Disease
Published Date: 2/27/2026
Notice
Summary
The FDA just gave Sentynl Therapeutics a special priority review voucher for their new rare pediatric disease drug, ZYCUBO, which treats Menkes disease in kids. This voucher speeds up future FDA reviews, helping get important medicines to patients faster. The approval happened on January 12, 2026, and this voucher could also be sold or used to speed up other drug reviews, potentially saving time and money.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
ZYCUBO Approved for Menkes Disease
If you have a child with Menkes disease, the FDA approved ZYCUBO (copper histidinate) for treatment on January 12, 2026. This approval means pediatric patients with Menkes disease have an FDA‑approved treatment option.
Priority Review Voucher Can Speed Reviews
The FDA issued a Rare Pediatric Disease Priority Review Voucher tied to ZYCUBO; the voucher can be used or sold to speed the FDA review of another drug. If you or someone you care for needs a rare‑disease medicine, using or selling this voucher can help get other important drugs to patients faster and may save time and money.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-06478 — Determination of Regulatory Review Period for Purposes of Patent Extension; VYLOY
The FDA has officially set the review period for VYLOY, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind VYLOY, giving them a chance to extend their patent protection and potentially boost profits. If anyone thinks the dates are wrong or wants to challenge the company’s review speed, they must act by June 2 or September 30, 2026.
2026-06481 — Determination of Regulatory Review Period for Purposes of Patent Extension; HYMPAVZI
The FDA has set the official review period for HYMPAVZI, a new human biological product, so its patent holder can apply for extra patent time. This affects the company behind HYMPAVZI and anyone interested in patent extensions. If you think the dates are wrong or want to challenge the company’s diligence, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06480 — Determination of Regulatory Review Period for Purposes of Patent Extension; EMRELIS
The FDA has officially set the review period for EMRELIS, a medicine patent, so the patent owner can apply for extra protection time. If anyone thinks the dates are wrong, they have until June 2, 2026, to speak up. Also, people can challenge whether the patent owner was diligent during the review by September 30, 2026. This affects patent holders and could impact how long they keep exclusive rights to their product.
2026-06479 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENFLONSIA
The FDA has set the official review period for ENFLONSIA, a human biological product, so its patent holder can apply for extra patent time. This affects the company behind ENFLONSIA and anyone interested in patent rules. If you think the dates are wrong or want to challenge the company’s review speed, you have until June 2 or September 30, 2026, to speak up—potentially impacting patent length and market exclusivity.
2026-06477 — Determination of Regulatory Review Period for Purposes of Patent Extension; ENCELTO
The FDA has officially set the review period for ENCELTO, a medicine patent, so the company can apply to extend its patent protection. This affects the drug maker by potentially giving them more time to exclusively sell ENCELTO, which can mean more money. If anyone thinks the dates are wrong or the company wasn’t diligent, they have until June 2 or September 30, 2026, to speak up.
2026-06483 — Determination of Regulatory Review Period for Purposes of Patent Extension; INJECTAFER
The FDA has officially set the review period for INJECTAFER, a drug patent up for extension. This means the company can apply to extend their patent protection, potentially keeping their exclusive rights longer and impacting competition and pricing. If anyone thinks the dates are wrong or the company wasn’t diligent, they can speak up by June 2 or September 30, 2026.
Previous / Next Documents
Previous: 2026-03924 — Certain Beverage Brewing Products and Components Thereof; Notice of Institution of Investigation
Adrian Rivera Maynez Enterprises is asking the U.S. International Trade Commission to investigate certain beverage brewing products that might be breaking their patents. If the investigation agrees, some products could be blocked from being sold or imported into the U.S., which could shake up the market soon. This means companies selling these products should watch out for possible legal changes and restrictions starting in 2026.
Next: 2026-03926 — Commercial Driver's License Standards: Application for Exemption Renewal; Wilson Logistics
Wilson Logistics got the green light to keep their special exemption that lets a learner driver train without a fully licensed driver sitting right next to them—once the learner has passed their skills test. This renewal runs from February 24, 2026, to February 24, 2031, and keeps safety standards strong while giving Wilson Logistics some training flexibility. Drivers, trainers, and the company all benefit from this smart, safety-approved update with no extra costs.
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in